

Results 1Q21 - FLRY3

April 2021



Disclosure

This presentation may contain forward-looking statements. Such statements are not statements of historical facts and reflect the beliefs and expectations of the Company's management. The words "anticipates", "believes", "estimates", "expects", "forecasts", "plans", "predicts", "project", "targets" and similar words are intended to identify these statements, which necessarily involve known and unknown risks and uncertainties. Known risks and uncertainties include but are not limited to the impact of competitive services and pricing market acceptance of services, service transactions by the Company and its competitors, regulatory approval, currency fluctuations, changes in service mix offered, and other risks described in the Company's registration statement. Forward-looking statements speak only as of the date they are made and Grupo Fleury does not undertake any obligation to update them in light of new information or future developments.


All figures are compared to 1Q20 except when stated otherwise.

Highlights

- ✓ Gross Revenue reached the second highest historical level in the quarter, totaling R\$ 964.3 million, an increase of 25.1% in 1Q21.
- Client's home service showed significant growth for the fourth consecutive quarter, corresponding to 7.7% of Gross Revenue, an increase of 86% in the quarter.
- Since the beginning of the pandemic, approximately 2.7 million tests have been performed for Covid-19¹, with 1.3 million RT-PCR and 1.4 million serologies. In the quarter, the volume of tests performed was 597 thousand.
- Telemedicine services in full expansion, with more than 300 thousand consultations performed through Saúde iD.
- ✓ EBITDA of R\$ 285.5 million (+45.7%), with a margin of 31.9% (+450 bps) in 1Q21.
- ✓ Net Income of R\$ 118.6 million (+102.0%), with a net margin of 13.3% (+505 bps) in 1Q21.
- ✓ Operating Cash Generation of R\$ 199.2 million (+52.2%) in 1Q21.
- ✓ Return on Invested Capital (ROIC¹) without Goodwill LTM, considering the effects of IFRS-16 of 47.2%.
- ✓ NPS² improved when compared to 4Q20, reaching 73.1% in the PSCs and 81.5% in client's home service in 1Q21, as a result of the continuous efforts to improve the level of services in our PSCs.

¹ Updated on 04/28/2021, including RT-PCR and Serology | ² Net Promoter Score | ³ As of 1Q21, we will present the ROIC with the effects of IFRS-16

Evolution in the Number of Lives – Saúde iD




Representativeness of Saúde iD in the Group's Total Lives served

¹ In thousands | Does not consider B2B and acquired companies




Evolution of the Number of Consultations - Telemedicine Saúde iD




¹ In thousands

Consolidated Gross Revenue (R\$ MM)




Gross Revenue

Total Gross Revenue Variation YoY (%)




COVID-19 tests participation on the Gross Revenue (% of the total)





¹ Considering the Gross Revenue of RT-PCR and Sorology tests on the total Gross Revenue for each segment.

Gross Revenue


Patient Service Centers Performance




Costs and Expenses



EBITDA (R\$ MM) and Margin (%)





Net Income (R\$ MM) and Margin (%)





Cash Flow

Operating Cash Flow and CAPEX



ROIC and Net Promoter Score



¹ As of 1Q21, we will present the ROIC with the effects of IFRS-16

IR events with the market

Date	Event
May 18th	UBS BB XII Virtual Healthcare Day
May 19th	Itau CEO Healthcare Day
May 25th	BTG Pactual CEO Conference Brasil 2021
June 1st	Bank of America Merrill Lynch Healthcare Day
June 8th	Morgan Stanley Brazilian Healthcare Conference

[Click here](#) to access the complete calendar with the Market.

